Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
Eli Lilly has announced plans to acquire three companies for nearly $4 billion to enhance its research in infectious diseases. The acquisitions include Curevo, LimmaTech Biologics, and Vaccine Company, with respective deal values of $1.5 billion, $780 million, and $1.55 billion. Following the announcement, Eli Lilly's stock saw a 1.3% increase in premarket trading.
- ▪Eli Lilly plans to acquire three companies for almost $4 billion.
- ▪The companies being acquired are Curevo, LimmaTech Biologics, and Vaccine Company.
- ▪Eli Lilly's stock rose 1.3% in premarket trading after the announcement.
CNBC — Top files mainly under finance. We currently carry 510 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | CNBC — Top |
| Canonical URL | https://www.cnbc.com/2026/05/26/eli-lilly-stock-vaccine-deals-curevo-limmatech.html |
| Publication time | Tue, 26 May 2026 11:50:20 GMT |
| Retrieval time | 2026-05-26T11:52:48.624Z |
| Last seen | 2026-05-26T11:52:48.624Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | Bol_GQYJUrOy |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Eli Lilly on Tuesday announced plans to acquire three companies for almost $4 billion in cash, as it looks to expand its research and development business into infectious diseases.The company said it had agreed deals to buy Curevo, LimmaTech Biologics and Vaccine Company for $1.5 billion, $780 million and $1.55 billion, respectively. Shares of Eli Lilly rose 1.3% in premarket trading on the news."These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences," Daniel M. Skovronsky, chief scientific and product officer and president, said in a statement.This is breaking news story, please refresh for updates.
Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC — Top.
Discussion
0 commentsMore from CNBC — Top
